PAS
CLYM

Point72 Asia (Singapore)’s Climb Bio CLYM Stock Holding History

Point72 Asia (Singapore)’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$22K Sell
10,952
-3,133
-22% -$5.82K ﹤0.01% 699
2025
Q2 		$17.5K Buy
+14,085
New +$17.5K ﹤0.01% 746

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asia (Singapore)'s CLYM Position: Q3 2025 in Review

Point72 Asia (Singapore) reduced its Climb Bio (CLYM) stake by 22% in Q3 2025, selling an estimated $5.82K and leaving 10,952 shares worth $22K. The position accounts for ﹤0.01% of the portfolio, ranked #699.

Point72 Asia (Singapore) first reported a position in CLYM in Q2 2025 and has held it in 2 quarters since. 68 funds tracked by Wall St. Rank hold CLYM as of Q3 2025.

  • Point72 Asia (Singapore) held 10,952 shares of Climb Bio worth $22K as of Q3 2025.
  • Point72 Asia (Singapore) sold 3,133 Climb Bio shares in Q3 2025, an estimated $5.82K.
  • Climb Bio made up ﹤0.01% of Point72 Asia (Singapore)'s portfolio in Q3 2025, its #699 holding.
  • Point72 Asia (Singapore) first reported a position in Climb Bio in Q2 2025 and has held it in 2 quarters since.
  • 68 funds tracked by Wall St. Rank held Climb Bio as of Q3 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q3 2025, filed 14 Nov 2025.